KIT and neoplasm: There, even though we could see the complete inactivation of the downstream signaling pathway in UZLX-GIST2 (with KIT exon 9 mutation) or in GIST48, this effect did not translate into an additive effect on proliferation inhibition and tumor growth decrease that would be more pronounced than the one achieved with imatinib alone.